Image source: The Motley Fool.

Date

Wednesday, March 18, 2026 at 8:30 a.m. ET

Call participants

• Chief Executive Officer — William Grant
• Chief Financial Officer — Almog Adar

Need a quote from a Motley Fool analyst? Email [email protected]

Risks

• Revenue decline -- "At the same time, revenue for the fourth quarter and for the full year came in lower than estimated," due to the U.S. sales channel transition and distributor order timing for AlterG product line.
• Low cash reserves -- $2.2 million unrestricted cash at year-end, with operating cash usage of $16.8 million for the year, indicating dependence on successful transaction closing for near-term liquidity.

Takeaways

• Total revenue -- $22 million, representing a 14% decrease compared to $25.7 million in 2024.
• ReWalk Personal Exoskeleton revenue -- $8.5 million, largely unchanged from $8.9 million, with a 22% increase in units sold indicating higher adoption and demand.
• MyoCycle FES Bike revenue -- $600,000, down 50%, mainly due to shifting away from an exclusive distribution arrangement and focusing on the core portfolio.
• AlterG revenue -- $12.9 million, an 18% decline, driven by lower international sales and significant distributor order timing differences.
• Gross profit (GAAP) -- $8.4 million, or 38.2% of revenue, compared to $8.2 million and 32% in 2024, reflecting higher year-over-year margin.
• Gross profit (Non-GAAP) -- $9 million, or 41% of revenue, versus $11 million and 43%; decline attributed to lower volumes and increased tariffs and freight.
• Operating expenses (GAAP) -- $28.1 million, 25% lower than $37.6 million, due primarily to reduced impairment charges.
• Operating expenses (Non-GAAP) -- $24.1 million, down 12%, reflecting improved marketing productivity, sales efficiency, and reduced R&D after major program completions.
• Operating loss (GAAP) -- $19.7 million, a 33% improvement from $29.3 million the prior year, mainly because of lower impairment charges.
• Operating loss (Non-GAAP) -- $15.1 million, reduced by 9% compared to $16.6 million.
• Net loss (GAAP) -- $19.9 million, narrowing by 31% from $28.9 million.
• Net loss (Non-GAAP) -- $15.3 million, narrowing by 5% compared to $16.2 million.
• Operating cash usage -- $16.8 million, improved by 23% from $21.7 million due to stronger accounts receivable collection and lower inventory, partially offset by revenue decline relative to expenses.
• Year-end cash -- $2.2 million in unrestricted cash and cash equivalents recorded at December 31, 2025.
• Oramed loan -- Entered into a $3 million agreement in Q4 for near-term liquidity prior to transaction closing.
• Oramed strategic agreement -- Shareholder approval received; closing imminent, expected to deliver $10 million in convertible note A financing from Oramed and another investor.
• ReWalk qualified U.S. pipeline -- More than 104 qualified leads in process at year-end, reflecting the expanding reimbursement coverage.
• Germany pipeline -- 49 leads and 22 active rentals at year-end, with the latter historically converting to sales in three to six months.
• AlterG backlog -- 26 systems in backlog at year-end, providing future revenue visibility.
• Medicare Advantage reimbursement -- Coverage for ReWalk secured with Aetna (NYSE:AET), Humana (NYSE:HUM), and UnitedHealthcare (NYSE:UNH), together covering over 16 million U.S. lives.
• International expansion -- Post-CE Mark, accelerated ReWalk distribution throughout Europe, with Germany as the primary test market, and new entry into Mexico, Thailand, and UAE via Verita Neuro partnership.
• Skelable acquisition -- Purchased intellectual property and technology supporting development of an AI-powered upper extremity orthotic system for stroke rehabilitation; core Skelable engineering team added to Lifeward's organization.
• Upper body neuro rehab market opportunity -- Annual addressable U.S. market cited as 245,000 new stroke survivors and 4.6 million chronically disabled survivors.
• Upper extremity product timeline -- Regulatory pathway anticipated as 510(k) exempt, with timeline to market of 18-24 months if trajectory is maintained.
• Product pipeline -- Next-generation AlterG and ReWalk platforms, as well as upper body exoskeleton, in advanced development; all expected to expand the total addressable market.
• Guidance -- Management did not provide forward guidance due to ongoing business transformation and the pending Oramed deal.

Summary

Lifeward (LFWD 2.31%) announced a 14% revenue decline to $22 million, with both U.S. sales reorganization and the absence of a large distributor order contributing to the shortfall. The pending Oramed strategic transaction received shareholder approval and is set to provide a significant $10 million capital infusion as convertible notes. Management emphasized expansion into the metabolic therapeutics sector through the addition of ORMP-0801, an advanced oral insulin candidate, while also strengthening its rehabilitation pipeline through the Skelable acquisition and focused R&D investment. Cash reserves at year-end were limited, highlighting the need for timely transaction closure to fund upcoming initiatives and stabilize operations.

• William Grant cited his three decades of experience in metabolic health and commercialization as a key advantage for integrating both medtech and biotech product strategies.
• Lifeward expects efficiencies in marketing and sales to continue reducing core operating expenses, with increased R&D spending planned for new product introductions.
• The upper extremity exoskeleton is planned for accelerated market entry due to anticipated 510(k) exempt status and straightforward clinical requirements.
• International pipeline acceleration includes key geographies in Europe, Mexico, Thailand, and the UAE, supported by expanded partnerships.

Industry glossary

• 510(k) exempt: U.S. regulatory pathway allowing select medical devices to enter the market without the need for premarket clearance if the product is deemed low risk and meets specific criteria.
• CE Mark: A European regulatory designation that enables commercial distribution of medical devices across the European Economic Area following conformity assessment.
• FES (Functional Electrical Stimulation): Medical technology using electrical currents to stimulate nerves and muscles to aid movement, commonly applied in rehabilitation contexts.

Full Conference Call Transcript

William Grant: Good morning, and thanks, everyone, for joining us on the call today. Before we get into the details of the quarter and the year, I want to start with what we believe is fundamental to the Lifeward investment thesis today. We're executing against a strategy to build a leading, diversified, biomedical innovation company with multiple technology platforms and strong clinical foundations. Importantly, we're establishing a clear line of sight to scale through continued progress in reimbursement, commercial execution and product innovation.

Our strategic transaction with Oramed gives us meaningful access to capital to support our growth initiatives, and we remain focused on driving the business toward cash flow positive operations while investing in innovations that will define the future of the company. An important milestone for Lifeward is the pending close of our strategic agreement with Oramed following the receipt of shareholder approval last week. This partnership significantly strengthens our financial foundation and expands our strategic scope. I want to thank our shareholders for approving the transaction. Your support reflects confidence in the strategy we've laid out and the opportunity ahead of us. I also want to acknowledge our outstanding team at Oramed.

They've been great partners, and I look forward to building a long-term collaboration that creates meaningful value for patients, partners and shareholders. Personally, this opportunity is particularly exciting for me given my background in diabetes at Medtronic and metabolic health at Bristol-Myers Squibb. One of the more compelling assets in this partnership is ORMP-0801 an advanced clinical-stage oral insulin candidate that has the potential to fundamentally change how insulin therapy is delivered. Because oral insulin is delivered through the gut, it goes to the liver first mimicking the path of natural insulin for the pancreas.

For the patient, this can mean better regulation of glucose production by the liver and less circulating through the body, which will reduce weight gain and the risk of hypoglycemia. Multiple studies have shown no increased risk of hypoglycemia compared with placebo. This is an important distinction in the insulin field and if successfully developed, could meaningfully improve both patient safety and treatment adherence. We're excited about the potential of this program and believe it represents meaningful addition to Lifeward's long-term innovation platform. The current plan is to move forward with the new U.S. study.

The unique funding structure for the clinical program also allows Lifeward to maintain pinpoint operational focus on profitability and cash generation of our portfolio while simultaneously gaining exposure to the potential substantial upside of a large-scale biotech opportunity. Another major recent step forward for the company is the acquisition of intellectual property and technology from Skelable. This transaction was structured in a very capital-efficient way, and we believe it will prove to be highly accretive as the technology advances to market. The technology we acquired supports development of a powered upper extremity orthotic system with AI capabilities designed to assist functional movement and restore function in individuals with weakened or paralyzed arms and hands, particularly following stroke.

The device is intended to enable patients to perform activities of daily living that would otherwise be very difficult or impossible while supporting therapeutic goals such as muscle reeducation and improved range of motion. In the U.S. alone, this upper body neuro rehab system can help an estimated 245 -- 245,000 newly diagnosed stroke survivors annually and an addition of 4.6 million stroke survivors who remain disabled. With plans to develop and launch a product, we are eager to get to this patient population. What makes this acquisition particularly valuable, not only the technology itself, but it's the team that comes with it. As you know, you don't have the opportunity for outside in inflection points that often.

So the core Skelable engineering group will be joining Lifeward bringing more than 60 years of combined experience across electrical, software, mechanical and industrial design. That experience is incredibly important as we integrate the technology into our development framework, bring the original engineering team with the platform ensures continuity of knowledge and allows for a disciplined transfer of intellectual property design intent and technical architecture into our broader pipeline. The stellar engineering team will also be a core team working on the advance advancing and the rest of our neuro rehab product portfolio. We believe this platform expands Lifeward's leadership into whole body robotic rehabilitation and opens a significant market opportunity with neuro rehabilitation.

In fact, the new platform is highly complementary to our existing ReWalk ecosystem. We will leverage our established clinical relationships, distribution network and reimbursement channels to accelerate the time of commercialization. And I want to underscore here that Lifeward's focus in robotic rehabilitative technologies is exactly that to rehabilitate and help the human return to full function or return to as much function as humanly possible. We are committed to continuous innovation, deploying the most advanced robotics and AI technologies to restore full health and quality of life to a broadening patient population. Now turning to our established core neuro rehab business. We continue to make important progress across reimbursement, clinical partnerships and global distribution during the year.

At the same time, revenue for the fourth quarter and for the full year came in lower than estimated, and there were two primary drivers behind that. First, in the United States, we implemented a major change in our sales and distribution infrastructure. As we discussed on our third quarter call, we began a transition toward a hybrid model that combines our internal direct sales efforts with external channel partnerships. Building those partnerships takes time. They don't translate into revenue overnight, so you're not seeing the full impact of those changes in our numbers yet. Within this restructured also our sales organization internally to better align with our business evolving.

Today, our commercial efforts operate across three focused areas: First, our direct-to-patient channel, which supports individuals pursuing a personal ReWalk system through the reimbursement process; second, our capital equipment sales team, which focuses on institutional customers, including rehabilitation centers, hospitals and support medicine facilities for AlterG. We believe there are substantial untapped opportunities here that can better be served by our capital equipment sales team; the third is a dedicated reimbursement and payer engagement function that works across all payers to expand coverage and support both our direct and distribution channels.

As you know, reimbursement is a critical driver of our long-term growth strategy and building a stronger payer engagement capability is essential to expanding patient access, accelerating adoption of our technologies. It's critical for our patients to be able to access our technologies through their health care benefit in their community. We believe this structure will ultimately improve the overall sales process strengthen payer engagement and drive greater adoption. As those changes mature, we expect to see the positive effects begin to show in the coming quarters. The second factor affecting the revenue was the decline in AlterG sales tied to a specific distributor dynamic. In 2024, one of our distributors made a very large inventory purchase.

That distributor had not placed that comparable in 2025. A which created a year-over-year comparison headwind. Based on our discussions with them, we expect that purchasing to normalize again in 2026. Despite those temporary dynamics, the underlying fundamentals of the business remain strong. Reimbursement coverage continues to expand. Clinical demand remains solid, and we're building a growing backlog and qualified pipeline. Recently, we achieved reimbursement for coverage of ReWalk in the three largest Medicare Advantage insurers in the U.S., Aetna, Humana and UnitedHealthcare, which collectively represent over 16 million covered lives in America. We also made meaningful progress expanding international distribution for ReWalk.

Following the receipt of the CE Mark in September of last year, we have been accelerating our efforts across Europe. Germany has become our primary international test market and is proving to be valuable insights to reimbursement pathways, clinical adoption and patient demand. International markets represent a significant long-term opportunity for the ReWalk platform, and we're opportunistic about the trajectory we're seeing so far. Through an agreement with Verita Neuro and a partner-led capital-efficient structure, we expanded distribution into Mexico, Thailand and the United Arab Emirates. Our core neuro rehabilitation business serves as a powerful innovation engine for Lifeward. We have multiple next-generation technologies in development.

A new version of AlterG should be expected and our next-generation ReWalk is currently targeted. And with the scalable IP and technology acquisition, we expect our upper body exoskeleton platform to reach the market, too. Together, these programs significantly expand our addressable market and strengthen our long-term product pipeline. I will now turn the call over to Almog to review our financial results and provide additional detail on operating performance and liquidity position. Before doing that, please note, given the significant transformation Lifeward has recently undergone and the pending close of our agreement with Oramed, we will not be providing guidance at this time.

We remain excited about the long-term prospects and cautiously optimistic about the growth in our core MedTech business, together with continued improvements in operating expenses will help drive the company towards a positive cash flow in the near future.

Almog Adar: Thank you, Mark. Today, as we have a lot to share about the existing transition Lifeward is making into a diversified biomedical company, I will review highlights of our full year 2025 results. You may refer to the detailed report for the quarter and full year in our press release, which was issued earlier today. Please keep in mind that as we review our results, I will discuss both GAAP and non-GAAP figures. The non-GAAP results exclude the items detailed in the reconciliation table in today's earnings release and, in our view, provide a clear picture of the company's underlying operating performance.

I encourage you to refer to the GAAP results in the reconciliation table as we go through the 2025 financials. Revenue for the year ended December 31, 2025, was $22 million compared to $25.7 million in 2024, a decrease of approximately 14%. Revenue from the sales of Free work personal exoskeleton was relatively flat at $8.5 million in 2025 compared to $8.9 million in 2024. Importantly, while revenue remained relatively stable, the number of units sold increased by 22% year-over-year, reflecting growing adoption of the ReWalk personal system and increased reimbursement driven demand. We believe this trend reflects continued progress in reimbursement coverage and increasing clinical adoption of the ReWalk personal system.

Revenue of the MyoCycle FES bike declined by 50% to $600,000, primarily reflecting the transition away from an exclusive distribution arrangement and the company's strategic focus on its core product portfolio. Revenue from the sales of AlterG products and services was $12.9 million, a decline of 18% from 2024. This decrease was primarily due to lower international sales, including timing factor related to one international distributor that had placed larger orders in the fourth quarter of 2024. We believe the decline largely reflects the timing of distributor orders, which can vary from period to period. Across both the ReWalk and AlterG product lines, our commercial pipeline remains healthy.

For the ReWalk product line, we closed the year with a pipeline of more than 104 qualified leads in process in the United States. Our growing medical-related accounts receivable balance also positions us well for future cash inflows. In Germany, we had 49 leads in process at year-end included 22 active rentals, which historically convert to sales within 3 to 6 months. For AlterG, we closed the quarter with 26 systems in backlog. Move to gross profit. Gross profit increased in 2025 to $8.4 million or 38.2% of revenue compared to $8.2 million or 32% of revenues in 2024.

On a non-GAAP basis, 2025 gross profit was $9 million or 41% of revenue compared to $11 million or 43% of revenue in 2024. The year-over-year decrease in adjusted gross margin was primarily driven by lower sales volume, which reduced absorption of fixed manufacturing overhead as well as higher tariffs and freight expenses. Operating expenses declined by 25% to $28.1 million in 2025 compared to $37.6 million in 2024. This decrease primarily reflects the impact of larger impairment charge recognized in the fourth quarter of 2024 related to certain acquired intangible assets compared to a $2.8 million goodwill impairment charge recorded in 2025.

On a non-GAAP basis, adjusted operating expenses also declined by 12% to $24.1 million in 2025 compared to $27.5 million in 2024. This decrease was primarily driven by improved productivity in marketing and sales operations, greater efficiency in reimbursement activities and lower R&D spending following the completion of major development programs. We expect the positive trend in marketing and sales efficiencies to continue into 2026. At the same time, we plan to increase investment in R&D as we advance new products to market, including our recently acquired power upper body exoskeleton. Operating loss narrowed by 33% in 2025 to $19.7 million compared to $29.3 million in 2024.

This was primarily due to a $9.8 million impairment charge recognized in the fourth quarter of 2024. On a non-GAAP basis, operating loss narrowed by 9% to $15.1 million compared to $16.6 million in 2024. Net loss narrowed by 31% to $19.9 million in 2025 compared to $28.9 million in 2024. On a non-GAAP basis, adjusted net loss narrowed by 5% to $15.3 million in 2025 compared to $16.2 million in the prior year. We also reduced operating cash usage by 23% to $16.8 million in 2025 compared to $21.7 million in 2024. The improvement was primarily driven by better working capital management, including stronger collection of receivable and lower inventory levels.

The benefit was partially offset by lower revenues relative to operating expenses. During the fourth quarter, we entered into a $3 million loan agreement with Oramed providing additional capital support to further strengthen our liquidity position as we move towards closing the broader strategic transaction. As of December 31, 2025, Lifeward had $2.2 million in unrestricted cash and cash equivalents on its balance sheet. We expect to finalize the closing of our strategic transaction with Oramed in the coming days with only a few remaining administrative steps. Upon closing of the transaction, the company expects to receive $10 million in a convertible note A financing from Oramed and another investor as described in January 13, 2026, press release.

With that, I will turn the call back to Mark for closing remarks.

William Grant: To close, I want to return to the broader picture. Lifeward today is evolving into a diversified biomedical innovation company built on multiple complementary platforms, neuro rehabilitation, robotic, and metabolic therapeutics. Each of these areas offers meaningful growth potential and together, they position us to build a company with scale and impact of $1 billion-plus enterprise over time. With Oramed partnership, we now have access to the funding necessary to execute this strategy, and we will remain disciplined in our approach as we approach as we move the company forward to cash flow positive operations. We're confident in our road map, confident in the strength of our technology platforms and confident in our ability to execute. Thank you, everyone.

Operator: [Operator Instructions] And our first question today comes from Yale Jen at Laidlaw & Company.

Yale Jen: Congrats on the transformation. Maybe a few questions related to that. The first one is for the Oramed part technology. How would you think -- I mean, if the focus is on this oral insulin, how would that align with your -- I mean, first of all, how much work is needed to be done before get approved? And secondly, how would that align with your -- or leverage your commercial infrastructure?

William Grant: Yes. A lot of that question is going to have to be answered once we actually get through the close. But in short, right, I've got a long history, almost 3 decades in the metabolic space. And so this is really drive synergies across med tech and biotech. When you're looking at a diversified portfolio and a durable company, I think it positions us really well. I also think that if you look at how we're approaching the market and moving from a centralized approach of selling patient to patient to decentralize and excluding commercial models, having a biotechnology like this fits. We become an innovation company that then allows us to actually move into a decentralized approach.

Yale Jen: Okay. And maybe just if I may add, in terms of your current commercial infrastructure. How was the product like that to be able to leverage your current availability or you would need to build up a new added more new sales or other to be able to accomplish for successful commercialization.

William Grant: Yes. So I think the beauty of this is in the short term, while we continue to go through clinical trials, this is completely funded through the acquisition and allows us to actually keep completely focused on our core business while we continue to expand the opportunity with Oramed. So the good news is, yes, in the short term, it's actually fully funded in motion. And secondarily, just to expand on your question of what does it mean for our distribution network. Look, I've got multiple years of experience developing these networks and bringing products to market. So when the commercialization opportunity presents itself, we'll be adept at that as a company.

So it's something I'm going to pull through while we're going through the clinical trials.

Yale Jen: And maybe just one more question here. In terms of your upper extremity robotic assistance. I guess you suggest that it will take 12 to 18 to 24 months will be to complete. Could you give us a little bit specific time line in terms of does the study need to be done, the regulatory process. And maybe lastly, how do you see the market of that and how that complements your ReWalk system?

William Grant: Yes. So if we're able to stay in the current space that we believe we're going to be in encoding, this becomes a 510(k) exempt product. So as we go through innovation and bringing it to commercialization, the barriers to entry are quite low. But we still have more to discover as we go through and making sure we meet the appropriate coding and making sure that we fall into that category, but that's a trajectory that we believe that we see and that we've discovered during diligence. And as far as the 18 to 24 months, as far as 18 to 24 months, yes, we're confident in hitting that. We've already started that work.

Yale Jen: Would that be some sort of clinical study needed? And any time line you can suggest on that as well as the time line after that for the regulatory process?

William Grant: We haven't outlined the exact clinical study yet. What we do know is it won't need to be high-end numbers, and it's probably going to be more oriented to a safety or bench study. just show efficacy and safety. So it's not something that takes a large amount of time given the barrier, given the hurdles to entry are low. You don't have to have a high clinical bar.

Yale Jen: Okay. Maybe last question here is in terms of this -- the upper extremity, there seems to be other competitor in the space currently. And how do you see your benefits over others to be commercially successful?

William Grant: Look, that's a great question. And I think that there's so much to come that I'm going to reserve the opportunity to answer that at a later date. As I see it today, we're going to enter the market differently. And while there may be competitors in this space, our job is actually for expansion into new areas. So let me get a little bit under my belt before I actually address that one. But I think you guys are going to be excited about the simplicity and efficacy of this product.

Operator: Our next question comes from Swayampakula Ramakanth with H.C. Wainright.

Swayampakula Ramakanth: This is RK from H.C Wainwright. Mark and Almog, a broad high-level question similar to what Yale was just asking. I think about 2 or almost 3 years ago now, the previous management brought in AlterG, to kind of expand on their -- within the med tech mobility space. And then just trying to integrate that whole business together when Mark, you came onboard. And now you're kind of pulling another lever into kind of biotech sort of space. Plus on top of that, you added this upper extremity portion of it. So in general, for an investor trying to follow the story. How should he or she think about this at a high level?

And is there if they are concerned that you're going in multiple places without kind of strengthening or deepening in one area, is that a fair assessment or people are not really understanding the strategy?

William Grant: Okay. Great to hear your voice, and thank you for the question. Look, I think the fundamentals of commercialization weren't as strong or stable as they should have been. I think what everybody should expect is getting products to the market through the right channel with the right coverage are most important. What you're going to see over time is us evolving into an innovation company that understands the channels to go to market. It's not going to matter whether it's a biotech or a med tech product.

I'm going to use the experience that I've based over the last 30 years and also the experience that we're building within the organization through our payer and channel team. to exploit these opportunities. And so I think the expectation is, hey, listen, you've got a very diversified med tech and biotech portfolio, which should be very exciting, durable. It should be able to weather the storms of what comes and goes for us, also give us a lot of different opportunities to move products into the space. what you're going to see is this will become an execution company that understands reimbursement and commercialization better than anybody else. As you know, but I'll make sure the broader audience does.

I've actually authored thousands of payer and commercial contracts across the globe and bringing that discipline here into the business, coupled with the new operational discipline, that's what we should be known for is getting the right products through the right channels at the right time with operational discipline that allows us to scale. I think the one thing that's probably a little confusing to everybody, so I'll get the elephant in the room, being a core neuro medtech company and then moving into biologics, does it make sense from an investor standpoint, it absolutely makes sense.

Who wouldn't want the aspects of having a biologic on the hook inside the organization who also wouldn't want to have it on the hook for somebody who's known for executional discipline and commercial channels. So I think that I'm going to have to work over time on my talk track around what it looks like when you have multiple backgrounds. But if you look across some of the larger organizations in the world, having a biodiverse med tech company is important and having those differentials in the same ecosystem is doable.

Swayampakula Ramakanth: Okay. So talking about execution, initially, we were under the impression that your full year revenues would be within the range of $24 million to $26 million. But obviously, it's higher. So what drove this additional execution? And do you think some of the things that you brought to the table are helping out. And that's the sort of stuff that we should be looking for in 2026 and 2027.

William Grant: I'm going to describe this company a little bit because I think it's important to the answer. I view the company as a start-up even though it's actually got a long tenured history. And the reason I do that is because the commercialization and understanding of the reimbursement pathways weren't explicit. And so as we've integrated those into the organization and started to pave the way for a growing the reimbursement, which everybody has seen. Since I've joined, we've started to garner better payer and global coverage, and we'll continue to do that over time. We're still not there, right? So we still have another 12 to 18 months until we maximize the coverage across our products.

And I think that's important. That discipline did not exist. Secondarily, there was a lot of lift and shift of manufacturing that was going on as I entered the business I would love to tell you it was as planful as it should have been, and it wasn't. So the good news is I've done it before. So we actually have cleaned up some of those areas. We're looking for the highest quality products on the market, delivered on time and we've gone through those disciplined executions here inside the company and started to put the framework so we can lift and shift and do this with other products.

So I think really the importance of building the business fundamentally, and I've said this before from a foundation from the bottom up. The good news is there wasn't a lot here when we actually build the bottom from -- I know what good looks like. So when we build it from the bottom up, we'll have the operational procedures in place. to bring in new technologies. We'll also have the reimbursement understanding and a team that's well adept across a multitude of products, whether it's biotech or med tech. And then lastly, we'll have the channels for distribution already set up and going. But those three areas are core to us as we go forward.

Swayampakula Ramakanth: Okay. One last question from me before I get back into the queue. In terms of placements, for Medicare beneficiaries this year, obviously, it was a record? And is there a way for you to quantify the backlog that you currently have as you enter 2026?

William Grant: RK, there is -- and you guys know that we've been getting to the data as we've expanded our payer coverage, though, we're going back through the qualified leads and pulling more and more into the pipeline. That's new since we've got a lot of reimbursement coverage. I think what's exciting is the 22% growth in units year-over-year. I think you need to stay hyperfocused on that and hold us to that unit number. You're going to see that expand as we move through this quarter and into next. But the pipeline is not solidified right now because the reimbursement is growing.

So the line of sight is actually growing, which is good news, but I don't have the exact numbers for you today.

Operator: And that concludes our question-and-answer session. I'd like to turn the conference back over to the company for any closing remarks.

William Grant: Listen, I want to thank everybody for showing up today. I appreciate the support. We're excited about the journey that we're getting ready to head on and can't wait to report out next time. So thanks, everybody. Have a great day.

Operator: Thank you, sir. That concludes today's conference call. We thank you all for attending today's presentation. You may now disconnect your lines, and have a wonderful day.